OptimizeRx Corporation

NasdaqCM:OPRX Lagerbericht

Marktkapitalisierung: US$116.9m

OptimizeRx Zukünftiges Wachstum

Future Kriterienprüfungen 3/6

Für OptimizeRx wird ein Gewinn- und Umsatzwachstum von 28.1% bzw. 4.8% pro Jahr prognostiziert, während der Gewinn je Aktie voraussichtlich um 24.1% pro Jahr steigen soll.

Wichtige Informationen

28.1%

Wachstumsrate der Gewinne

24.14%

EPS-Wachstumsrate

Healthcare Services Gewinnwachstum21.2%
Wachstumsrate der Einnahmen4.8%
Zukünftige Eigenkapitalrenditen/a
Analystenabdeckung

Good

Zuletzt aktualisiert08 Apr 2026

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

OPRX: Share Repurchases And Margin Gains Will Support Future Upside Potential

The analyst price target for OptimizeRx has moved from $32 to $20 as analysts factor in softer 2026 revenue expectations, lower revenue growth assumptions, falling peer multiples, and a higher discount rate, partly offset by improved profit margin forecasts and support from the new $10m share repurchase authorization. Analyst Commentary Recent research updates show that while price targets on OptimizeRx have been reset lower, several bullish analysts still highlight positive angles around execution, profitability, and capital allocation.

OPRX: Profit Execution And US$10m Buybacks Will Support Future Upside

Analysts have trimmed the blended price target for OptimizeRx to $14.50, reflecting softer 2026 revenue expectations, reduced revenue visibility, and lower peer multiples, partially offset by improved profit forecasts and support from the new $10m share repurchase authorization. Analyst Commentary Street research on OptimizeRx has turned more cautious on the revenue outlook through 2026, but there is still a split between what bullish analysts focus on and what more bearish analysts are worried about.

OPRX: Profit Focus And Buybacks Will Support Future Share Upside

Analysts have lowered their average price targets for OptimizeRx into the low to mid teens in dollar terms, citing reduced 2026 revenue visibility, softer pharma marketing budgets, pressure from peer multiples, and a greater focus on profitability and share repurchases. Analyst Commentary Street research on OptimizeRx has converged around lower price targets but with different degrees of optimism on execution, growth prospects, and valuation.

OPRX: Margin Discipline And Buybacks Will Support Future Upside Potential

Analysts have reduced the fair value estimate for OptimizeRx from $24.33 to $14.50, citing lower revenue growth expectations, reduced revenue visibility into 2026, and lower peer P/E multiples. These factors are partly offset by firmer profit margin forecasts and buy ratings that remain in place across several firms.

OPRX: Expanded Point Of Care Network Will Support Further Upside

Analysts have fine tuned their OptimizeRx price target to $24.33. This reflects updated assumptions around the discount rate, long term revenue growth, profit margin and future P/E multiple.

OPRX: New Data Partnerships Will Support Long Term Earnings Power

Analysts now maintain their price target for OptimizeRx at $17.00, reflecting updated assumptions for discount rate, revenue growth, profit margin, and future P/E that they view as broadly offsetting each other. What's in the News Announced a data collaboration with Experian at CES 2026 to connect OptimizeRx Micro-Neighborhood audiences with Experian's identity graph for onboarding, curation, and measurement of consumer audiences at scale (Client Announcements).

OPRX: Q3 Outperformance And 2026 Guidance Will Strengthen Long Term Earnings Power

Analysts have lifted their average price targets on OptimizeRx into a US$21 to US$32 range, citing stronger than guided Q3 performance, improved visibility after 2024, and expectations for ongoing double digit growth with expanding margins. Analyst Commentary Street research after the Q3 report has centered on stronger than guided results and higher price targets, with analysts highlighting improved earnings and better visibility beyond 2024.

OPRX: Q3 Execution Rebound And 2026 Guidance Will Support Further Upside

Analysts have lifted their blended price targets on OptimizeRx to a range of US$21 to US$32, citing stronger than guided Q3 revenue and EPS, improved visibility after 2024 execution issues, and continuing momentum that supports expectations for double digit growth with expanding margins. Analyst Commentary Across the Street, bullish analysts are taking Q3 as a sign that OptimizeRx may be getting back on track after earlier execution issues, and they have shifted their valuation ranges higher as a result.

OPRX: Higher Guidance And Margin Expansion Will Reshape Long Term Earnings Power

Analysts have lifted their fair value estimate for OptimizeRx from US$11.00 to US$17.00, reflecting higher price targets supported by recent revenue and EPS outperformance, improved growth visibility, and expectations for margin expansion. Analyst Commentary Street research on OptimizeRx has been broadly positive around the latest quarter, with several firms raising their price targets after revenue and EPS outperformance and clearer guidance.

OPRX Will Extend Double Digit Revenue Trajectory With New Multi Year Partnerships

Analysts have lifted their price target on OptimizeRx by $5 to $32 per share, citing consistently strong quarterly outperformance, improving visibility after last year's weak execution, and a more durable outlook for double digit revenue growth and expanding margins. Analyst Commentary Bullish analysts are increasingly aligned around a constructive view of OptimizeRx, pointing to a series of price target hikes following its latest quarterly results.

OPRX: Recurring Revenue Shift And 2026 Guidance Will Drive Future Upside

Analysts have nudged their price targets on OptimizeRx higher, with recent increases across the Street ranging from about $1 to $10 per share to reflect stronger than expected Q3 revenue and EPS, improved visibility, and confidence in sustained double digit growth and margin expansion. Analyst Commentary Bullish analysts highlighted that the latest quarter materially exceeded revenue expectations, driving meaningful EPS upside and reinforcing confidence in a durable, double digit growth profile.

OPRX: Multi-Year Guidance and Recurring Revenue Will Drive Upside Momentum

OptimizeRx's analyst price target has increased from $22 to approximately $24.33 per share. This reflects ongoing revenue outperformance and improved visibility that analysts attribute to strong quarterly results and the company's growing momentum.

OptimizeRx Corporation's (NASDAQ:OPRX) 33% Share Price Plunge Could Signal Some Risk

Nov 23
OptimizeRx Corporation's (NASDAQ:OPRX) 33% Share Price Plunge Could Signal Some Risk

OPRX: Expanding Margins and Subscription Model Will Drive Shareholder Value Forward

OptimizeRx's analyst fair value target has been raised from $19 to $22.00 per share. This change reflects stronger quarterly results, improved growth prospects, and expanding profit margins, according to analysts.

Is OptimizeRx (NASDAQ:OPRX) Using Too Much Debt?

Oct 07
Is OptimizeRx (NASDAQ:OPRX) Using Too Much Debt?

Are Investors Undervaluing OptimizeRx Corporation (NASDAQ:OPRX) By 39%?

Aug 27
Are Investors Undervaluing OptimizeRx Corporation (NASDAQ:OPRX) By 39%?

Pharmaceutical Digital Engagement Will Unlock Future Value

Despite near-term cautious revenue guidance, analysts remain optimistic on OptimizeRx due to Q2 earnings outperformance, improved management transparency, and ongoing strategic initiatives, maintaining the consensus price target at $19.00. Analyst Commentary Bullish analysts highlight OptimizeRx’s Q2 revenues and adjusted EBITDA significantly surpassing forecasts.

Even With A 33% Surge, Cautious Investors Are Not Rewarding OptimizeRx Corporation's (NASDAQ:OPRX) Performance Completely

May 09
Even With A 33% Surge, Cautious Investors Are Not Rewarding OptimizeRx Corporation's (NASDAQ:OPRX) Performance Completely
User avatar

A Subscription Model And EHR Network Will Reshape Healthcare

Transitioning to a subscription-based model aims to enhance revenue predictability and improve net margins with recurring income.

Is OptimizeRx Corporation (NASDAQ:OPRX) Expensive For A Reason? A Look At Its Intrinsic Value

Apr 06
Is OptimizeRx Corporation (NASDAQ:OPRX) Expensive For A Reason? A Look At Its Intrinsic Value

We Think OptimizeRx (NASDAQ:OPRX) Has A Fair Chunk Of Debt

Mar 08
We Think OptimizeRx (NASDAQ:OPRX) Has A Fair Chunk Of Debt

At US$6.29, Is It Time To Put OptimizeRx Corporation (NASDAQ:OPRX) On Your Watch List?

Feb 14
At US$6.29, Is It Time To Put OptimizeRx Corporation (NASDAQ:OPRX) On Your Watch List?

Market Might Still Lack Some Conviction On OptimizeRx Corporation (NASDAQ:OPRX) Even After 30% Share Price Boost

Dec 15
Market Might Still Lack Some Conviction On OptimizeRx Corporation (NASDAQ:OPRX) Even After 30% Share Price Boost

Does OptimizeRx (NASDAQ:OPRX) Have A Healthy Balance Sheet?

Nov 16
Does OptimizeRx (NASDAQ:OPRX) Have A Healthy Balance Sheet?

OptimizeRx (NASDAQ:OPRX) Is Carrying A Fair Bit Of Debt

Jul 30
OptimizeRx (NASDAQ:OPRX) Is Carrying A Fair Bit Of Debt

OptimizeRx Corporation's (NASDAQ:OPRX) 36% Jump Shows Its Popularity With Investors

Jan 09
OptimizeRx Corporation's (NASDAQ:OPRX) 36% Jump Shows Its Popularity With Investors

Gewinn- und Umsatzwachstumsprognosen

NasdaqCM:OPRX - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
DatumUmsatzGewinneFreier CashflowBargeld aus operativen TätigkeitenDurchschn. Anz. Analysten
12/31/20271219N/AN/A5
12/31/20261116N/AN/A7
12/31/202510951919N/A
9/30/202511001212N/A
6/30/2025105-101010N/A
3/31/202594-1567N/A
12/31/202492-2045N/A
9/30/202488-24-1-2N/A
6/30/202483-18-2-2N/A
3/31/202478-18-6-5N/A
12/31/202372-18-8-7N/A
9/30/202363-1402N/A
6/30/202362-1424N/A
3/31/202362-1466N/A
12/31/202262-111011N/A
9/30/202263-1067N/A
6/30/202264-733N/A
3/31/202264-333N/A
12/31/202161001N/A
9/30/2021571-1-1N/A
6/30/2021521-1-1N/A
3/31/202147-1-1-1N/A
12/31/202043-2-6-6N/A
9/30/202034-6-6-5N/A
6/30/202029-7-7-6N/A
3/31/202027-5-8-6N/A
12/31/201925-3-3-2N/A
9/30/201924-1N/A1N/A
6/30/2019241N/A3N/A
3/31/2019220N/A2N/A
12/31/2018210N/A1N/A
9/30/2018190N/A0N/A
6/30/201816-1N/A-2N/A
3/31/201814-1N/A-2N/A
12/31/201712-2N/A-1N/A
9/30/201710-2N/A-2N/A
6/30/20179-2N/A-1N/A
3/31/20178-2N/A0N/A
12/31/20168-2N/A0N/A
9/30/20167-2N/A0N/A
6/30/20168-1N/A0N/A
3/31/20167-1N/A0N/A
12/31/20157-1N/A1N/A
9/30/201570N/A1N/A
6/30/201570N/A0N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: OPRXDas prognostizierte Gewinnwachstum (28.1% pro Jahr) liegt über der Sparquote (3.4%).

Ertrag vs. Markt: OPRXDie Erträge des Unternehmens (28.1% pro Jahr) werden voraussichtlich schneller wachsen als der Markt US (15.8% pro Jahr).

Hohe Wachstumserträge: OPRXEs wird erwartet, dass die Erträge des Unternehmens in den nächsten 3 Jahren erheblich steigen werden.

Einnahmen vs. Markt: OPRXDie Einnahmen des Unternehmens (4.8% pro Jahr) werden voraussichtlich langsamer wachsen als der Markt US (11.1% pro Jahr).

Hohe Wachstumseinnahmen: OPRXDie Einnahmen des Unternehmens (4.8% pro Jahr) werden voraussichtlich langsamer wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: Unzureichende Daten, um festzustellen, ob die Eigenkapitalrendite von OPRX in 3 Jahren voraussichtlich hoch sein wird

Wachstumsunternehmen entdecken

7D

1Y

7D

1Y

7D

1Y

Unternehmensanalyse und Finanzdaten Status

DatenZuletzt aktualisiert (UTC-Zeit)
Unternehmensanalyse2026/05/01 05:48
Aktienkurs zum Tagesende2026/05/01 00:00
Gewinne2025/12/31
Jährliche Einnahmen2025/12/31

Datenquellen

Die in unserer Unternehmensanalyse verwendeten Daten stammen von S&P Global Market Intelligence LLC. Die folgenden Daten werden in unserem Analysemodell verwendet, um diesen Bericht zu erstellen. Die Daten sind normalisiert, was zu einer Verzögerung bei der Verfügbarkeit der Quelle führen kann.

PaketDatenZeitrahmenBeispiel US-Quelle *
Finanzdaten des Unternehmens10 Jahre
  • Gewinn- und Verlustrechnung
  • Kapitalflussrechnung
  • Bilanz
Konsensschätzungen der Analysten+3 Jahre
  • Finanzielle Vorausschau
  • Kursziele der Analysten
Marktpreise30 Jahre
  • Aktienkurse
  • Dividenden, Splits und Aktionen
Eigentümerschaft10 Jahre
  • Top-Aktionäre
  • Insiderhandel
Verwaltung10 Jahre
  • Das Führungsteam
  • Direktorium
Wichtige Entwicklungen10 Jahre
  • Ankündigungen des Unternehmens

* Beispiel für US-Wertpapiere, für nicht-US-amerikanische Wertpapiere werden gleichwertige regulatorische Formulare und Quellen verwendet.

Sofern nicht anders angegeben, beziehen sich alle Finanzdaten auf einen Jahreszeitraum, werden aber vierteljährlich aktualisiert. Dies wird als Trailing Twelve Month (TTM) oder Last Twelve Month (LTM) Daten bezeichnet. Erfahren Sie mehr.

Analysemodell und Schneeflocke

Einzelheiten zu dem Analysemodell, mit dem dieser Bericht erstellt wurde, finden Sie auf unserer Github-Seite. Außerdem bieten wir Leitfäden zur Verwendung unserer Berichte und Tutorials auf YouTube an.

Erfahren Sie mehr über das Weltklasse-Team, das das Simply Wall St-Analysemodell entworfen und entwickelt hat.

Metriken für Industrie und Sektor

Unsere Branchen- und Sektionskennzahlen werden alle 6 Stunden von Simply Wall St berechnet. Details zu unserem Verfahren finden Sie auf Github.

Analysten-Quellen

OptimizeRx Corporation wird von 12 Analysten beobachtet. 7 dieser Analysten hat die Umsatz- oder Gewinnschätzungen übermittelt, die als Grundlage für unseren Bericht dienen. Die von den Analysten übermittelten Daten werden im Laufe des Tages aktualisiert.

AnalystEinrichtung
Anderson SchockB. Riley Securities, Inc.
Constantine DavidesCitizens JMP Securities, LLC
Eric MartinuzziLake Street Capital Markets, LLC